Doximity (NYSE:DOCS) Shares Up 4.3% – Should You Buy?

Doximity, Inc. (NYSE:DOCS)’s stock price rose 4.3% on Thursday. The stock traded as high as $29.00 and last traded at $28.8890. 674,629 shares traded hands during mid-day trading, a decline of 83% from the average session volume of 3,981,646 shares. The stock had previously closed at $27.69.

Doximity News Roundup

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: RBC Capital reaffirmed its Buy rating on Doximity, providing a bullish counterpoint to the litigation headlines and suggesting the firm sees potential in the company’s long-term outlook. RBC Capital Reaffirms Their Buy Rating on Doximity
• Neutral Sentiment: Multiple law firms publicized the same pending securities class action and reminded investors that November 16, 2026 is the deadline to seek appointment as lead plaintiff. The notices primarily seek participation from shareholders who bought Doximity securities between August 8, 2024, and May 13, 2026, rather than announcing separate new lawsuits. Bronstein Gewirtz Grossman Doximity Class Action Notice
• Negative Sentiment: The lawsuit alleges Doximity misled investors about business momentum. Claims highlighted in the notices include alleged loss of market share to competitors, slowing revenue growth, reduced fiscal 2026 guidance, and a subsequent failure to meet that lowered outlook. The allegations also question disclosures about Newsfeed engagement, banner advertising, e-newsletters, and pharmaceutical customers’ changing advertising spending. These claims have not been proven. SueWallSt Doximity Class Action Notice
• Negative Sentiment: An insider sale was also reported: Kira Scherer Wampler sold 2,000 Doximity shares. The transaction is small relative to the company’s market value, but insider selling can modestly weigh on sentiment. Doximity Insider Share Sale

Analysts Set New Price Targets

Several analysts recently issued reports on DOCS shares. Canaccord Genuity Group set a $36.00 target price on shares of Doximity in a research report on Friday, August 7th. Stifel Nicolaus set a $27.00 price target on shares of Doximity in a research report on Tuesday, September 8th. Piper Sandler reiterated an “overweight” rating and set a $47.00 price target (up from $42.00) on shares of Doximity in a research note on Friday, August 7th. Zacks Research raised shares of Doximity from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Freedom Capital lowered Doximity from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $31.95.

Doximity Stock Up 4.3%

The firm has a market cap of $5.15 billion, a PE ratio of 34.00, a P/E/G ratio of 21.74 and a beta of 1.22. The firm’s fifty day simple moving average is $25.60 and its two-hundred day simple moving average is $23.32.

Doximity (NYSE:DOCS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.13. The business had revenue of $156.62 million during the quarter. Doximity had a net margin of 25.48% and a return on equity of 18.06%. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.36 earnings per share. As a group, analysts anticipate that Doximity, Inc. will post 0.74 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Kira Wampler sold 2,000 shares of the business’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $28.91, for a total value of $57,820.00. Following the transaction, the director directly owned 27,923 shares in the company, valued at $807,253.93. The trade was a 6.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Siddharth Sitaram sold 2,077 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $26.02, for a total value of $54,043.54. Following the completion of the transaction, the chief accounting officer directly owned 96,045 shares of the company’s stock, valued at approximately $2,499,090.90. This trade represents a 2.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 16,637 shares of company stock worth $533,688. 31.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Doximity

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Versant Capital Management Inc raised its stake in Doximity by 1,176.9% during the 3rd quarter. Versant Capital Management Inc now owns 1,826 shares of the company’s stock valued at $52,000 after purchasing an additional 1,683 shares during the period. Parallel Advisors LLC grew its holdings in Doximity by 111.0% during the 1st quarter. Parallel Advisors LLC now owns 2,560 shares of the company’s stock valued at $60,000 after buying an additional 1,347 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Doximity by 937.7% in the first quarter. EverSource Wealth Advisors LLC now owns 2,833 shares of the company’s stock worth $66,000 after buying an additional 2,560 shares in the last quarter. Leonteq Securities AG lifted its holdings in shares of Doximity by 65.6% in the first quarter. Leonteq Securities AG now owns 2,912 shares of the company’s stock worth $68,000 after buying an additional 1,154 shares in the last quarter. Finally, Rockefeller Capital Management L.P. boosted its position in shares of Doximity by 264.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 3,014 shares of the company’s stock worth $133,000 after acquiring an additional 2,187 shares during the last quarter. Institutional investors own 87.19% of the company’s stock.

About Doximity

Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources.

The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals.

Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products.